🔗 Visit the ClinicalTrials.gov page for NCT01531673
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression. | Sci Transl Med | 2014 | 1.64 |
| 2 | State of progress in treating cystic fibrosis respiratory disease. | BMC Med | 2012 | 0.96 |
| 3 | Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis. | Drug Des Devel Ther | 2013 | 0.87 |
| 4 | CFTR Modulators for the Treatment of Cystic Fibrosis. | P T | 2014 | 0.81 |
| 5 | On the mechanism of gating defects caused by the R117H mutation in cystic fibrosis transmembrane conductance regulator. | J Physiol | 2016 | 0.79 |
| 6 | Interaction non grata between CFTR's correctors and potentiators. | Ann Transl Med | 2015 | 0.76 |
| 7 | CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis. | Front Pharmacol | 2016 | 0.75 |